Clinical Trial Update: Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial

View source ↗

Summary

This update discusses the long-term risk of a second primary malignancy in patients with chronic myeloid leukemia treated with imatinib in the French SPIRIT tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Chronic Myeloid Leukemia (CML) | Status: ENROLLING_BY_INVITATION